AstraZeneca

New study identifies gene associated with strong immune response to COVID-19 vaccines

They also looked at DNA samples from children who had participated in clinical trials for the Oxford-AstraZeneca vaccine.

UK Government announces £800m boost to support innovation and improve patient safety

The NIHR BRCs have supported almost 60, 000 experimental medicine research studies over the past nine years including the development of the Oxford AstraZeneca COVID-19 vaccine, as well as promising

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

Tezspire demonstrated reduced annualised rate of asthma exacerbations. AstraZeneca’s (AZ) Tezspire (tezepelumab) has been granted marketing authorisation in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) for

EC approves Alexion's Ultomiris as generalised myasthenia gravis treatment

The European Commission (EC) has approved Aexion’s – part of the AstraZeneca Rare Disease group – Ultomiris (ravulizumab) in Europe as an add-on to standard therapy for generalised myasthenia gravis (gMG).

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

AstraZeneca’s (AZ) Tezspire (tezepelumab) has been approved by the European Commission (EC) for use as an add-on maintenance treatment in patients 12 years and older with severe asthma, the

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]